CDPPB

Last updated

CDPPB
CDPPB Structure.svg
Identifiers
  • 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard 100.222.673 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C23H18N4O
Molar mass 366.424 g·mol−1
3D model (JSmol)
  • c3ccccc3-n1nc(-c4ccccc4)cc1NC(=O)c(c2)cccc2C#N
  • InChI=1S/C23H16N4O/c24-16-17-8-7-11-19(14-17)23(28)25-22-15-21(18-9-3-1-4-10-18)26-27(22)20-12-5-2-6-13-20/h1-15H,(H,25,28) X mark.svgN
  • Key:BKUIZWILNWHFHD-UHFFFAOYSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

CDPPB is a drug used in scientific research which acts as a positive allosteric modulator selective for the metabotropic glutamate receptor subtype mGluR5. [1] [2] [3] It has antipsychotic effects in animal models, [4] and mGluR5 modulators are under investigation as potential drugs for the treatment of schizophrenia, [5] as well as other applications. [6] [7]

References

  1. ↑ Lindsley CW, Wisnoski DD, Leister WH, O'brien JA, Lemaire W, Williams DL, Burno M, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Duggan ME, Hartman GD, Conn PJ, Huff JR (November 2004). "Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo". Journal of Medicinal Chemistry. 47 (24): 5825–8. doi:10.1021/jm049400d. PMID   15537338.
  2. ↑ de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, Conn PJ (June 2006). "Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes". Journal of Medicinal Chemistry. 49 (11): 3332–44. doi:10.1021/jm051252j. PMID   16722652.
  3. ↑ Chen Y, Nong Y, Goudet C, Hemstapat K, de Paulis T, Pin JP, Conn PJ (May 2007). "Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses". Molecular Pharmacology. 71 (5): 1389–98. doi:10.1124/mol.106.032425. PMID   17303702. S2CID   7004830.
  4. ↑ Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL (April 2005). "A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models". The Journal of Pharmacology and Experimental Therapeutics. 313 (1): 199–206. doi:10.1124/jpet.104.079244. PMID   15608073. S2CID   14946765.
  5. ↑ Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL, Sur C, Kinney GG (2006). "Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia". Current Topics in Medicinal Chemistry. 6 (8): 771–85. doi:10.2174/156802606777057599. PMID   16719816.
  6. ↑ Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B (October 2007). "Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex". Biological Psychiatry. 62 (7): 739–46. doi:10.1016/j.biopsych.2006.12.003. PMC   2910402 . PMID   17511968.
  7. ↑ Gass JT, Olive MF (April 2009). "Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory". Biological Psychiatry. 65 (8): 717–20. doi:10.1016/j.biopsych.2008.11.001. PMC   2870714 . PMID   19100966.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.